211 related articles for article (PubMed ID: 22808277)
1. PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes.
Putz EM; Prchal-Murphy M; Simma OA; Forster F; Koenig X; Stockinger H; Piekorz RP; Freissmuth M; Müller M; Sexl V; Zebedin-Brandl E
PLoS One; 2012; 7(7):e40852. PubMed ID: 22808277
[TBL] [Abstract][Full Text] [Related]
2. Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
Zebedin E; Simma O; Schuster C; Putz EM; Fajmann S; Warsch W; Eckelhart E; Stoiber D; Weisz E; Schmid JA; Pickl WF; Baumgartner C; Valent P; Piekorz RP; Freissmuth M; Sexl V
Blood; 2008 Dec; 112(12):4655-64. PubMed ID: 18684865
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
5. Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity.
Kojima Y; Kawasaki-Koyanagi A; Sueyoshi N; Kanai A; Yagita H; Okumura K
Biochem Biophys Res Commun; 2002 Aug; 296(2):328-36. PubMed ID: 12163021
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity.
Medana I; Li Z; Flügel A; Tschopp J; Wekerle H; Neumann H
J Immunol; 2001 Jul; 167(2):674-81. PubMed ID: 11441070
[TBL] [Abstract][Full Text] [Related]
7. A calcium optimum for cytotoxic T lymphocyte and natural killer cell cytotoxicity.
Zhou X; Friedmann KS; Lyrmann H; Zhou Y; Schoppmeyer R; Knörck A; Mang S; Hoxha C; Angenendt A; Backes CS; Mangerich C; Zhao R; Cappello S; Schwär G; Hässig C; Neef M; Bufe B; Zufall F; Kruse K; Niemeyer BA; Lis A; Qu B; Kummerow C; Schwarz EC; Hoth M
J Physiol; 2018 Jul; 596(14):2681-2698. PubMed ID: 29368348
[TBL] [Abstract][Full Text] [Related]
8. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation.
Balaji KN; Schaschke N; Machleidt W; Catalfamo M; Henkart PA
J Exp Med; 2002 Aug; 196(4):493-503. PubMed ID: 12186841
[TBL] [Abstract][Full Text] [Related]
9. CTLs respond with activation and granule secretion when serving as targets for T-cell recognition.
Milstein O; Hagin D; Lask A; Reich-Zeliger S; Shezen E; Ophir E; Eidelstein Y; Afik R; Antebi YE; Dustin ML; Reisner Y
Blood; 2011 Jan; 117(3):1042-52. PubMed ID: 21045195
[TBL] [Abstract][Full Text] [Related]
10. The exocytosis of lytic granules is impaired in Vti1b- or Vamp8-deficient CTL leading to a reduced cytotoxic activity following antigen-specific activation.
Dressel R; Elsner L; Novota P; Kanwar N; Fischer von Mollard G
J Immunol; 2010 Jul; 185(2):1005-14. PubMed ID: 20543108
[TBL] [Abstract][Full Text] [Related]
11. Differential implication of protein kinase C isoforms in cytotoxic T lymphocyte degranulation and TCR-induced Fas ligand expression.
Pardo J; Buferne M; Martínez-Lorenzo MJ; Naval J; Schmitt-Verhulst AM; Boyer C; Anel A
Int Immunol; 2003 Dec; 15(12):1441-50. PubMed ID: 14645153
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
13. ECH, an epoxycyclohexenone derivative that specifically inhibits Fas ligand-dependent apoptosis in CTL-mediated cytotoxicity.
Mitsui T; Miyake Y; Kakeya H; Osada H; Kataoka T
J Immunol; 2004 Mar; 172(6):3428-36. PubMed ID: 15004142
[TBL] [Abstract][Full Text] [Related]
14. Serglycin-deficient cytotoxic T lymphocytes display defective secretory granule maturation and granzyme B storage.
Grujic M; Braga T; Lukinius A; Eloranta ML; Knight SD; Pejler G; Abrink M
J Biol Chem; 2005 Sep; 280(39):33411-8. PubMed ID: 16046402
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic lipase-related protein 2 (PLRP2) induction by IL-4 in cytotoxic T lymphocytes (CTLs) and reevaluation of the negative effects of its gene ablation on cytotoxicity.
Alves BN; Leong J; Tamang DL; Elliott V; Edelnant J; Redelman D; Singer CA; Kuhn AR; Miller R; Lowe ME; Hudig D
J Leukoc Biol; 2009 Sep; 86(3):701-12. PubMed ID: 19451396
[TBL] [Abstract][Full Text] [Related]
16. Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production.
Chiang SC; Theorell J; Entesarian M; Meeths M; Mastafa M; Al-Herz W; Frisk P; Gilmour KC; Ifversen M; Langenskiöld C; Machaczka M; Naqvi A; Payne J; Perez-Martinez A; Sabel M; Unal E; Unal S; Winiarski J; Nordenskjöld M; Ljunggren HG; Henter JI; Bryceson YT
Blood; 2013 Feb; 121(8):1345-56. PubMed ID: 23287865
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity.
Makrigiannis AP; Hoskin DW
J Immunol; 1997 Nov; 159(10):4700-7. PubMed ID: 9366393
[TBL] [Abstract][Full Text] [Related]
18. Expression and function of synaptotagmin VII in CTLs.
Fowler KT; Andrews NW; Huleatt JW
J Immunol; 2007 Feb; 178(3):1498-504. PubMed ID: 17237398
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis of epitope-specific antiretroviral cytotoxic T lymphocytes via Fas ligand-Fas interactions.
Rich RF; Green WR
Viral Immunol; 2006; 19(3):424-33. PubMed ID: 16987061
[TBL] [Abstract][Full Text] [Related]
20. Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity.
Davis JE; Smyth MJ; Trapani JA
Eur J Immunol; 2001 Jan; 31(1):39-47. PubMed ID: 11169436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
